Cargando…
Aprocitentan: A new development of resistant hypertension
As the blood pressure threshold for commencing antihypertensive treatment diminishes, the cohort suffering from resistant hypertension (RH) correspondingly expands. Notwithstanding the availability of known antihypertensive medications, there exists a conspicuous lacuna in therapeutic options specif...
Autores principales: | Yao, Yao, Fan, Bin, Yang, Bin, Jia, Zixuan, Li, Bao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339369/ https://www.ncbi.nlm.nih.gov/pubmed/37334561 http://dx.doi.org/10.1111/jch.14686 |
Ejemplares similares
-
Aprocitentan: New insights
por: Varzideh, Fahimeh, et al.
Publicado: (2022) -
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021) -
Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
por: Heidari Nejad, Sayeh, et al.
Publicado: (2023) -
Comparison of endoscopic submucosal dissection with surgical gastrectomy for early gastric cancer: An updated meta-analysis
por: Li, Hua, et al.
Publicado: (2019) -
Value of intravoxel incoherent motion in detecting and staging liver fibrosis: A meta-analysis
por: Ye, Zheng, et al.
Publicado: (2020)